Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Engineered mischarged transfer RNAs for correcting pathogenic missense mutations

ABSTRACT: Engineered mischarged transfer RNAs for correcting pathogenic missense mutations

PROVIDER: PRJNA991914 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR25181400_1.fastq.gz	Fastqsanger.gz
	SRR25181400_2.fastq.gz	Fastqsanger.gz
	SRR25181401_1.fastq.gz	Fastqsanger.gz
	SRR25181401_2.fastq.gz	Fastqsanger.gz
	SRR25181402_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 120

Similar Datasets

Engineered mischarged transfer RNAs for correcting pathogenic missense mutations [MSR-seq]

Project description:Missense mutations account for nearly 50% of pathogenic mutations in human genetic diseases, most lack effective treatments. Gene therapies, CRISPR-based gene editing, and RNA therapies including transfer RNA (tRNA) modalities are common strategies for potential treatments of genetic diseases. However, reported tRNA therapies are for nonsense mutations, how tRNAs can be engineered to correct missense mutations have not been explored. Here, we describe missense correcting tRNAs (mc-tRNAs) as a potential therapeutic modality for correcting pathogenic missense mutations. Mc-tRNAs are engineered tRNAs that are charged with one amino acid and read codons of another amino acid in translation in human cells. We first developed a series of fluorescence protein (FP)-based reporters that indicate successful correction of missense mutations via restoration of fluorescence signals. We engineered mc-tRNAs that effectively corrected Serine and Arginine missense mutations in the reporters and confirmed the amino acid substitution by protein mass spectrometry and mc-tRNA expression by tRNA sequencing. We examined the transcriptome response to the expression of mc-tRNAs and found some mc-tRNAs induced minimum transcriptomic changes. Furthermore, we applied an Arg-tRNAGln(CUG) mc-tRNA to rescue the autolytic activity of a pathogenic CAPN3 Arg-to-Gln mutant involved in limb-girdle muscular dystrophy type 2A. These results establish a versatile pipeline for mc-tRNA engineering and demonstrate the potential of mc-tRNA as an alternative therapeutic platform for the treatment of genetic disorders.

2024-01-04 | GSE236623 | GEO

Engineered mischarged transfer RNAs for correcting pathogenic missense mutations [mRNA-seq]

2024-01-04 | GSE236622 | GEO

Engineered mischarged transfer RNAs for correcting pathogenic missense mutations [mRNA-seq]

Project description:Engineered mischarged transfer RNAs for correcting pathogenic missense mutations [mRNA-seq]

| PRJNA991919 | ENA

Engineered mischarged transfer RNAs for correcting pathogenic missense mutations [MSR-seq]

Project description:Engineered mischarged transfer RNAs for correcting pathogenic missense mutations [MSR-seq]

| PRJNA991918 | ENA

Engineered mischarged transfer RNAs for correcting pathogenic missense mutations

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-01-03 | GSE236624 | GEO

Multi-modal investigation reveals pathogenic features of diverse DDX3X missense mutations

Project description:De novo mutations in the RNA binding protein DDX3X cause neurodevelopmental disorders including DDX3X syndrome and autism spectrum disorder. Amongst ~200 mutations identified to date, half are missense. While DDX3X loss of function is known to impair neural cell fate, how the landscape of missense mutations impacts neurodevelopment is almost entirely unknown. Here, we integrate transcriptomics, proteomics, and live imaging to demonstrate clinically diverse DDX3X missense mutations perturb neural development via distinct cellular and molecular mechanisms. Using mouse primary neural progenitors, we investigate four recurrently mutated DDX3X missense variants, from clinically severe (2) to mild (2). While clinically severe mutations impair neurogenesis, mild mutations have only a modest impact on cell fate. Moreover, expression of severe mutations leads to profound neuronal death. Using a proximity labeling screen in neural progenitors, we discover DDX3X missense variants have unique protein interactors. We observe notable overlap amongst severe mutations, suggesting common mechanisms underlying altered cell fate and survival. Transcriptomic analysis and subsequent cellular investigation highlights new pathways associated with DDX3X missense variants, including upregulated DNA Damage Response. Notably, clinically severe mutations exhibit excessive DNA damage in neurons, associated with aberrant cytoplasmic DNA:RNA hybrids and formation of stress granules. These findings highlight aberrant RNA metabolism and DNA damage in DDX3X-mediated neuronal cell death. In sum our findings reveal new mechanisms by which clinically distinct DDX3X missense mutations differentially impair neurodevelopment.

2025-01-06 | GSE279078 | GEO

Glutamine missense suppression transfer RNAs inhibit polyglutamine aggregation

Project description:Mass spectrometry confirmed Ala mis-incorporation in polyQ, demonstrating misincorporation at each position in polyQ at a level of ~10% Ala at Gln codons. Cells expressing the missense suppressor tRNAs showed no growth defect or significant changes in cytotoxicity. Our findings demonstrate that tRNA-dependent missense suppression of glutamine codons is well-tolerated in cells has the potential to modify and significantly reduce protein aggregation that causes HD.

2025-01-15 | PXD053115 | Pride

Ribosome profiling of selenoproteins in vivo reveals consequences of pathogenic Secisbp2 missense mutations

Project description:Re-coding of UGA codons as selenocysteine (Sec) codons in selenoproteins depends on a selenocysteine insertion sequence (SECIS) in the 3’ UTR of mRNAs of eukaryotic selenoproteins. SECIS-binding protein 2 (SECISBP2) increases the efficiency of this process. Pathogenic mutations in SECISBP2 reduce selenoprotein expression and lead to phenotypes associated with the reduction of deiodinase activities and selenoprotein N expression in humans. Two functions have been ascribed to SECISBP2: binding of SECIS elements in selenoprotein mRNAs and facilitation of co-translational Sec insertion. To separately probe both functions, we established here two mouse models carrying two pathogenic missense mutations in Secisbp2 previously identified in patients. We found that the C696R substitution in the RNAbinding domain abrogates SECIS binding and does not support selenoprotein translation above the level of a complete Secisbp2 null mutation. The R543Q missense substitution located in the selenocysteine insertion domain resulted in residual activity and caused reduced selenoprotein translation, as demonstrated by ribosomal profiling to determine the impact on UGA re-coding in individual selenoproteins. We found, however, that the R543Q variant is thermally unstable in vitro and completely degraded in the mouse liver in vivo, while being partially functional in the brain. The moderate impairment of selenoprotein expression in neurons led to astrogliosis and transcriptional induction of genes associated with immune responses. We conclude that differential SECISBP2 protein stability in individual cell types may dictate clinical phenotypes to a much greater extent than molecular interactions involving a mutated amino acid in SECISBP2 .

2019-07-26 | GSE119681 | GEO

Multi-modal investigation reveals pathogenic features of diverse DDX3X missense mutations

Project description:Multi-modal investigation reveals pathogenic features of diverse DDX3X missense mutations

| PRJNA1170309 | ENA

Engineered cell elongation promotes extracellular electron transfer of Shewanella oneidensis

Project description:Engineered cell elongation promotes extracellular electron transfer of Shewanella oneidensis

| PRJNA1022018 | ENA